NEO100 and High-Grade Meningioma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

NEO100 and High-Grade Meningioma — Stella

Recruiting

Back to Residual, Progressive or Recurrent Grade II or III Meningioma trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

United States

University of Southern California, Los Angeles, California

Saint John Cancer Institute, Santa Monica, California

Baylor Scott and White, Dallas, Texas

Key details

Phase

Safety & dosing

Sponsor

Neonc Technologies, Inc.

Enrollment target

~30 participants

Started

July 2022

Primary completion

December 2026

Age range

12 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov